Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12621322 | 1.00 | BTN3A1 (0.41) | BTN3A1MEN1KMT2ALMNAHTT | |
| SCHEMBL14627743 | 0.90 | SMN1; SMN2 (0.42) | BTN3A1MEN1KMT2AHTTHPGD | |
| SCHEMBL1274199 | 0.89 | BTN3A1 (0.43) | BTN3A1MEN1KMT2ALMNAHTT | |
| SCHEMBL14596594 | 0.88 | MEN1 (0.43) | BTN3A1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL29787448 | 0.88 | MEN1 (0.43) | BTN3A1MEN1KMT2ALMNANPSR1 | |
| SCHEMBL1273013 | 0.87 | BTN3A1 (0.45) | BTN3A1MEN1KMT2ALMNAL3MBTL1 | |
| SCHEMBL13242487 | 0.87 | ALDH1A1 (0.42) | BTN3A1MEN1KMT2ALMNAHPGD | |
| SCHEMBL12248659 | 0.87 | ALDH1A1 (0.42) | BTN3A1MEN1KMT2ALMNAHPGD | |
| SCHEMBL12621315 | 0.87 | TSHR (0.44) | BTN3A1MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL19206507 | 0.87 | MEN1 (0.42) | MEN1KMT2AHPGDALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210078970-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| EP-3486251-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2019-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078970-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | ABL1, FLT3, SRC | BTN3A1 4117/4885MEN1 1705/4885KMT2A 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.